Sutimlimab Disease Interactions
There are 4 disease interactions with sutimlimab.
Sutimlimab (applies to sutimlimab) autoimmune disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder
Sutimlimab may increase the risk for developing autoimmune diseases such as systemic lupus erythematosus (SLE). Patients with SLE or autoimmune disease with positive antinuclear antibody were excluded from clinical trials with sutimlimab. In clinical trials, some patients developed a relapse or worsening of autoimmune disease. Patients receiving sutimlimab should be monitored for signs/symptoms and managed medically.
Sutimlimab (applies to sutimlimab) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The effects of liver dysfunction on the pharmacokinetics of sutimlimab are unknown.
Sutimlimab (applies to sutimlimab) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Sutimlimab may increase susceptibility to serious infections, including those caused by encapsulated bacteria. If this drug is administered to patients with active systemic infections, close monitoring for signs/symptoms of worsening infection is recommended. Interruption of treatment should be considered in patients who are undergoing treatment for serious infection. Patients should be vaccinated and/or revaccinated against encapsulated bacteria according to clinical recommendations, ideally at least 2 weeks before starting treatment. Sutimlimab has not been studied in chronic infections such a hepatitis B, hepatitis C, or HIV.
Sutimlimab (applies to sutimlimab) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effects of severe renal dysfunction on the pharmacokinetics of sutimlimab are unknown.
Switch to professional interaction data
Sutimlimab drug interactions
There are 77 drug interactions with sutimlimab.
More about sutimlimab
- sutimlimab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.